nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—PTGS1—Thalidomide—leprosy	0.149	0.191	CbGbCtD
Irbesartan—PTGS1—Dapsone—leprosy	0.119	0.153	CbGbCtD
Irbesartan—CYP2C8—Rifampicin—leprosy	0.0831	0.107	CbGbCtD
Irbesartan—CYP2C8—Dapsone—leprosy	0.0686	0.0883	CbGbCtD
Irbesartan—CYP1A2—Thalidomide—leprosy	0.0664	0.0855	CbGbCtD
Irbesartan—CYP1A2—Rifampicin—leprosy	0.0643	0.0828	CbGbCtD
Irbesartan—CYP2C9—Thalidomide—leprosy	0.0599	0.077	CbGbCtD
Irbesartan—CYP2C9—Rifampicin—leprosy	0.058	0.0746	CbGbCtD
Irbesartan—CYP2C9—Dapsone—leprosy	0.0479	0.0616	CbGbCtD
Irbesartan—CYP3A4—Rifampicin—leprosy	0.0337	0.0434	CbGbCtD
Irbesartan—CYP3A4—Dapsone—leprosy	0.0278	0.0358	CbGbCtD
Irbesartan—Labyrinthine disorder—Thalidomide—leprosy	0.00954	0.0684	CcSEcCtD
Irbesartan—Inner ear disorder—Thalidomide—leprosy	0.00954	0.0684	CcSEcCtD
Irbesartan—JUN—peripheral nervous system—leprosy	0.0061	0.154	CbGeAlD
Irbesartan—JUN—skin epidermis—leprosy	0.00558	0.141	CbGeAlD
Irbesartan—JUN—nerve—leprosy	0.00476	0.12	CbGeAlD
Irbesartan—JUN—blood vessel—leprosy	0.00373	0.094	CbGeAlD
Irbesartan—Electrolyte imbalance—Thalidomide—leprosy	0.00286	0.0205	CcSEcCtD
Irbesartan—AGTR1—blood vessel—leprosy	0.00281	0.0708	CbGeAlD
Irbesartan—Proteinuria—Dapsone—leprosy	0.00266	0.0191	CcSEcCtD
Irbesartan—Protein urine present—Dapsone—leprosy	0.00262	0.0188	CcSEcCtD
Irbesartan—Raised liver function tests—Thalidomide—leprosy	0.00259	0.0186	CcSEcCtD
Irbesartan—Transient ischaemic attack—Thalidomide—leprosy	0.00237	0.017	CcSEcCtD
Irbesartan—Lymphopenia—Thalidomide—leprosy	0.00234	0.0168	CcSEcCtD
Irbesartan—Sexual dysfunction—Thalidomide—leprosy	0.00213	0.0153	CcSEcCtD
Irbesartan—JUN—eye—leprosy	0.00199	0.05	CbGeAlD
Irbesartan—Myasthenia—Thalidomide—leprosy	0.0019	0.0136	CcSEcCtD
Irbesartan—JUN—skin of body—leprosy	0.00173	0.0435	CbGeAlD
Irbesartan—JUN—Senescence and Autophagy in Cancer—TNFSF15—leprosy	0.00171	0.0394	CbGpPWpGaD
Irbesartan—Nasopharyngitis—Dapsone—leprosy	0.00152	0.0109	CcSEcCtD
Irbesartan—Muscular weakness—Dapsone—leprosy	0.0015	0.0107	CcSEcCtD
Irbesartan—Influenza—Dapsone—leprosy	0.00147	0.0105	CcSEcCtD
Irbesartan—Numbness—Thalidomide—leprosy	0.00144	0.0103	CcSEcCtD
Irbesartan—EDNRA—tendon—leprosy	0.00144	0.0363	CbGeAlD
Irbesartan—Pancreatitis—Dapsone—leprosy	0.00144	0.0103	CcSEcCtD
Irbesartan—Sensory loss—Thalidomide—leprosy	0.00138	0.0099	CcSEcCtD
Irbesartan—Jaundice cholestatic—Thalidomide—leprosy	0.00136	0.00976	CcSEcCtD
Irbesartan—Proteinuria—Thalidomide—leprosy	0.00136	0.00976	CcSEcCtD
Irbesartan—Protein urine present—Thalidomide—leprosy	0.00134	0.00963	CcSEcCtD
Irbesartan—Photosensitivity reaction—Dapsone—leprosy	0.00134	0.0096	CcSEcCtD
Irbesartan—Musculoskeletal stiffness—Thalidomide—leprosy	0.00133	0.00956	CcSEcCtD
Irbesartan—JUN—tendon—leprosy	0.00132	0.0331	CbGeAlD
Irbesartan—Drug interaction—Thalidomide—leprosy	0.00129	0.00925	CcSEcCtD
Irbesartan—Hyperuricaemia—Thalidomide—leprosy	0.00129	0.00925	CcSEcCtD
Irbesartan—Bone pain—Thalidomide—leprosy	0.00125	0.00896	CcSEcCtD
Irbesartan—PTGS1—blood vessel—leprosy	0.00124	0.0311	CbGeAlD
Irbesartan—Blood uric acid increased—Thalidomide—leprosy	0.00122	0.00874	CcSEcCtD
Irbesartan—Coordination abnormal—Thalidomide—leprosy	0.00122	0.00874	CcSEcCtD
Irbesartan—JUN—Apoptosis—LTA—leprosy	0.00121	0.0277	CbGpPWpGaD
Irbesartan—EDNRA—testis—leprosy	0.00119	0.0301	CbGeAlD
Irbesartan—Hyperkalaemia—Thalidomide—leprosy	0.00118	0.00843	CcSEcCtD
Irbesartan—Pharyngitis—Dapsone—leprosy	0.00116	0.00835	CcSEcCtD
Irbesartan—Blood urea increased—Thalidomide—leprosy	0.00113	0.0081	CcSEcCtD
Irbesartan—Aplastic anaemia—Thalidomide—leprosy	0.00112	0.00806	CcSEcCtD
Irbesartan—Tinnitus—Dapsone—leprosy	0.00109	0.00785	CcSEcCtD
Irbesartan—Oesophagitis—Thalidomide—leprosy	0.00109	0.00784	CcSEcCtD
Irbesartan—JUN—testis—leprosy	0.00109	0.0274	CbGeAlD
Irbesartan—Lightheadedness—Thalidomide—leprosy	0.00107	0.00768	CcSEcCtD
Irbesartan—JUN—nervous system—leprosy	0.00107	0.0269	CbGeAlD
Irbesartan—Pulmonary oedema—Thalidomide—leprosy	0.00106	0.00764	CcSEcCtD
Irbesartan—Erythema—Dapsone—leprosy	0.00102	0.00733	CcSEcCtD
Irbesartan—Diabetes mellitus—Thalidomide—leprosy	0.000999	0.00716	CcSEcCtD
Irbesartan—AGTR1—tendon—leprosy	0.000991	0.025	CbGeAlD
Irbesartan—Photosensitivity—Thalidomide—leprosy	0.000989	0.00709	CcSEcCtD
Irbesartan—JUN—Calcium signaling in the CD4+ TCR pathway—CD40LG—leprosy	0.000984	0.0226	CbGpPWpGaD
Irbesartan—Gastroenteritis—Thalidomide—leprosy	0.00098	0.00703	CcSEcCtD
Irbesartan—Vision blurred—Dapsone—leprosy	0.000963	0.0069	CcSEcCtD
Irbesartan—JUN—FAS pathway and Stress induction of HSP regulation—RIPK2—leprosy	0.000954	0.0219	CbGpPWpGaD
Irbesartan—Injury—Thalidomide—leprosy	0.000945	0.00678	CcSEcCtD
Irbesartan—Increased appetite—Thalidomide—leprosy	0.000924	0.00663	CcSEcCtD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—TLR1—leprosy	0.000921	0.0212	CbGpPWpGaD
Irbesartan—Vertigo—Dapsone—leprosy	0.000918	0.00658	CcSEcCtD
Irbesartan—Visual disturbance—Thalidomide—leprosy	0.000916	0.00657	CcSEcCtD
Irbesartan—Arthritis—Thalidomide—leprosy	0.000894	0.00641	CcSEcCtD
Irbesartan—Cough—Dapsone—leprosy	0.000892	0.00639	CcSEcCtD
Irbesartan—Cerebrovascular accident—Thalidomide—leprosy	0.000886	0.00636	CcSEcCtD
Irbesartan—Hyponatraemia—Thalidomide—leprosy	0.000872	0.00625	CcSEcCtD
Irbesartan—Affect lability—Thalidomide—leprosy	0.000855	0.00613	CcSEcCtD
Irbesartan—Face oedema—Thalidomide—leprosy	0.000838	0.00601	CcSEcCtD
Irbesartan—JUN—CD40/CD40L signaling—CD40LG—leprosy	0.000827	0.019	CbGpPWpGaD
Irbesartan—Mood swings—Thalidomide—leprosy	0.000823	0.0059	CcSEcCtD
Irbesartan—AGTR1—testis—leprosy	0.000821	0.0207	CbGeAlD
Irbesartan—Tachycardia—Dapsone—leprosy	0.000814	0.00584	CcSEcCtD
Irbesartan—AGTR1—nervous system—leprosy	0.000805	0.0203	CbGeAlD
Irbesartan—Liver function test abnormal—Thalidomide—leprosy	0.000802	0.00575	CcSEcCtD
Irbesartan—Orthostatic hypotension—Thalidomide—leprosy	0.000793	0.00569	CcSEcCtD
Irbesartan—Hypokalaemia—Thalidomide—leprosy	0.00079	0.00567	CcSEcCtD
Irbesartan—Breast disorder—Thalidomide—leprosy	0.000785	0.00563	CcSEcCtD
Irbesartan—Cramp muscle—Thalidomide—leprosy	0.000782	0.00561	CcSEcCtD
Irbesartan—Toxic epidermal necrolysis—Thalidomide—leprosy	0.000782	0.00561	CcSEcCtD
Irbesartan—JUN—IL12 signaling mediated by STAT4—HLA-DRB1—leprosy	0.000771	0.0177	CbGpPWpGaD
Irbesartan—Muscular weakness—Thalidomide—leprosy	0.000766	0.00549	CcSEcCtD
Irbesartan—JUN—MAP kinase activation in TLR cascade—RIPK2—leprosy	0.000758	0.0174	CbGpPWpGaD
Irbesartan—Abdominal distension—Thalidomide—leprosy	0.000756	0.00542	CcSEcCtD
Irbesartan—Dysphagia—Thalidomide—leprosy	0.000751	0.00538	CcSEcCtD
Irbesartan—Influenza—Thalidomide—leprosy	0.000751	0.00538	CcSEcCtD
Irbesartan—Pancreatitis—Thalidomide—leprosy	0.000736	0.00528	CcSEcCtD
Irbesartan—Angina pectoris—Thalidomide—leprosy	0.000731	0.00524	CcSEcCtD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—TLR1—leprosy	0.000719	0.0165	CbGpPWpGaD
Irbesartan—Neutropenia—Thalidomide—leprosy	0.000702	0.00503	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Thalidomide—leprosy	0.000698	0.005	CcSEcCtD
Irbesartan—JUN—MAP kinase activation in TLR cascade—NOD2—leprosy	0.000687	0.0158	CbGpPWpGaD
Irbesartan—Photosensitivity reaction—Thalidomide—leprosy	0.000685	0.00491	CcSEcCtD
Irbesartan—Weight increased—Thalidomide—leprosy	0.000683	0.0049	CcSEcCtD
Irbesartan—Gastrointestinal pain—Dapsone—leprosy	0.000682	0.00489	CcSEcCtD
Irbesartan—Hyperglycaemia—Thalidomide—leprosy	0.000677	0.00486	CcSEcCtD
Irbesartan—Pneumonia—Thalidomide—leprosy	0.000673	0.00483	CcSEcCtD
Irbesartan—Acute coronary syndrome—Thalidomide—leprosy	0.00066	0.00473	CcSEcCtD
Irbesartan—Body temperature increased—Dapsone—leprosy	0.000659	0.00473	CcSEcCtD
Irbesartan—Abdominal pain—Dapsone—leprosy	0.000659	0.00473	CcSEcCtD
Irbesartan—Renal failure—Thalidomide—leprosy	0.000658	0.00472	CcSEcCtD
Irbesartan—Myocardial infarction—Thalidomide—leprosy	0.000656	0.0047	CcSEcCtD
Irbesartan—Conjunctivitis—Thalidomide—leprosy	0.000651	0.00467	CcSEcCtD
Irbesartan—JUN—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—leprosy	0.000636	0.0146	CbGpPWpGaD
Irbesartan—Epistaxis—Thalidomide—leprosy	0.000631	0.00453	CcSEcCtD
Irbesartan—Agranulocytosis—Thalidomide—leprosy	0.000625	0.00448	CcSEcCtD
Irbesartan—Bradycardia—Thalidomide—leprosy	0.000612	0.00439	CcSEcCtD
Irbesartan—Rhinitis—Thalidomide—leprosy	0.000602	0.00432	CcSEcCtD
Irbesartan—Hepatitis—Thalidomide—leprosy	0.000601	0.00431	CcSEcCtD
Irbesartan—JUN—TRAF6 Mediated Induction of proinflammatory cytokines—RIPK2—leprosy	0.0006	0.0138	CbGpPWpGaD
Irbesartan—Hypoaesthesia—Thalidomide—leprosy	0.000598	0.00429	CcSEcCtD
Irbesartan—Pharyngitis—Thalidomide—leprosy	0.000596	0.00428	CcSEcCtD
Irbesartan—Urinary tract disorder—Thalidomide—leprosy	0.000593	0.00425	CcSEcCtD
Irbesartan—Oedema peripheral—Thalidomide—leprosy	0.000592	0.00424	CcSEcCtD
Irbesartan—AGTR1—Allograft Rejection—CD40LG—leprosy	0.000591	0.0136	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—IL10—leprosy	0.000591	0.0136	CbGpPWpGaD
Irbesartan—Urethral disorder—Thalidomide—leprosy	0.000589	0.00422	CcSEcCtD
Irbesartan—Visual impairment—Thalidomide—leprosy	0.000579	0.00415	CcSEcCtD
Irbesartan—JUN—Calcium signaling in the CD4+ TCR pathway—IFNG—leprosy	0.000578	0.0133	CbGpPWpGaD
Irbesartan—PTGS1—skin of body—leprosy	0.000572	0.0144	CbGeAlD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—CYLD—leprosy	0.000569	0.0131	CbGpPWpGaD
Irbesartan—JUN—IL12 signaling mediated by STAT4—IFNG—leprosy	0.000563	0.0129	CbGpPWpGaD
Irbesartan—Tinnitus—Thalidomide—leprosy	0.00056	0.00402	CcSEcCtD
Irbesartan—Cardiac disorder—Thalidomide—leprosy	0.000558	0.004	CcSEcCtD
Irbesartan—Angiopathy—Thalidomide—leprosy	0.000545	0.00391	CcSEcCtD
Irbesartan—JUN—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—leprosy	0.000544	0.0125	CbGpPWpGaD
Irbesartan—JUN—IL12 signaling mediated by STAT4—CD4—leprosy	0.000544	0.0125	CbGpPWpGaD
Irbesartan—JUN—MyD88 cascade initiated on plasma membrane—RIPK2—leprosy	0.000543	0.0125	CbGpPWpGaD
Irbesartan—Immune system disorder—Thalidomide—leprosy	0.000543	0.00389	CcSEcCtD
Irbesartan—Mediastinal disorder—Thalidomide—leprosy	0.000541	0.00388	CcSEcCtD
Irbesartan—Chills—Thalidomide—leprosy	0.000539	0.00387	CcSEcCtD
Irbesartan—JUN—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—RIPK2—leprosy	0.000538	0.0124	CbGpPWpGaD
Irbesartan—Arrhythmia—Thalidomide—leprosy	0.000537	0.00385	CcSEcCtD
Irbesartan—Vomiting—Dapsone—leprosy	0.00053	0.0038	CcSEcCtD
Irbesartan—JUN—MyD88 dependent cascade initiated on endosome—RIPK2—leprosy	0.000528	0.0121	CbGpPWpGaD
Irbesartan—Malnutrition—Thalidomide—leprosy	0.000523	0.00375	CcSEcCtD
Irbesartan—Headache—Dapsone—leprosy	0.000522	0.00375	CcSEcCtD
Irbesartan—JUN—TCR Signaling Pathway—RIPK2—leprosy	0.000519	0.0119	CbGpPWpGaD
Irbesartan—Flatulence—Thalidomide—leprosy	0.000515	0.0037	CcSEcCtD
Irbesartan—JUN—Calcium signaling in the CD4+ TCR pathway—IL2—leprosy	0.000514	0.0118	CbGpPWpGaD
Irbesartan—Tension—Thalidomide—leprosy	0.000513	0.00368	CcSEcCtD
Irbesartan—Dysgeusia—Thalidomide—leprosy	0.000512	0.00367	CcSEcCtD
Irbesartan—JUN—Toll Like Receptor 9 (TLR9) Cascade—RIPK2—leprosy	0.00051	0.0117	CbGpPWpGaD
Irbesartan—Nervousness—Thalidomide—leprosy	0.000508	0.00364	CcSEcCtD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—CD8A—leprosy	0.000504	0.0116	CbGpPWpGaD
Irbesartan—Muscle spasms—Thalidomide—leprosy	0.000503	0.00361	CcSEcCtD
Irbesartan—JUN—MyD88:Mal cascade initiated on plasma membrane—RIPK2—leprosy	0.000501	0.0115	CbGpPWpGaD
Irbesartan—JUN—MyD88:Mal cascade initiated on plasma membrane—TLR2—leprosy	0.000501	0.0115	CbGpPWpGaD
Irbesartan—JUN—IL12 signaling mediated by STAT4—IL2—leprosy	0.0005	0.0115	CbGpPWpGaD
Irbesartan—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IFNG—leprosy	0.000496	0.0114	CbGpPWpGaD
Irbesartan—Nausea—Dapsone—leprosy	0.000495	0.00355	CcSEcCtD
Irbesartan—Vision blurred—Thalidomide—leprosy	0.000493	0.00353	CcSEcCtD
Irbesartan—JUN—MyD88 cascade initiated on plasma membrane—NOD2—leprosy	0.000492	0.0113	CbGpPWpGaD
Irbesartan—Tremor—Thalidomide—leprosy	0.00049	0.00351	CcSEcCtD
Irbesartan—JUN—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—leprosy	0.000488	0.0112	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—IL10—leprosy	0.000486	0.0112	CbGpPWpGaD
Irbesartan—Ill-defined disorder—Thalidomide—leprosy	0.000485	0.00348	CcSEcCtD
Irbesartan—Anaemia—Thalidomide—leprosy	0.000483	0.00347	CcSEcCtD
Irbesartan—Agitation—Thalidomide—leprosy	0.000481	0.00345	CcSEcCtD
Irbesartan—JUN—MyD88-independent cascade—RIPK2—leprosy	0.000481	0.011	CbGpPWpGaD
Irbesartan—JUN—MyD88 dependent cascade initiated on endosome—NOD2—leprosy	0.000479	0.011	CbGpPWpGaD
Irbesartan—Angioedema—Thalidomide—leprosy	0.000478	0.00343	CcSEcCtD
Irbesartan—AGTR1—Allograft Rejection—HLA-DRB1—leprosy	0.000476	0.0109	CbGpPWpGaD
Irbesartan—Malaise—Thalidomide—leprosy	0.000472	0.00338	CcSEcCtD
Irbesartan—Vertigo—Thalidomide—leprosy	0.00047	0.00337	CcSEcCtD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—TLR2—leprosy	0.000469	0.0108	CbGpPWpGaD
Irbesartan—Syncope—Thalidomide—leprosy	0.000469	0.00336	CcSEcCtD
Irbesartan—Leukopenia—Thalidomide—leprosy	0.000468	0.00336	CcSEcCtD
Irbesartan—JUN—Toll Like Receptor 9 (TLR9) Cascade—NOD2—leprosy	0.000462	0.0106	CbGpPWpGaD
Irbesartan—Loss of consciousness—Thalidomide—leprosy	0.00046	0.0033	CcSEcCtD
Irbesartan—Cough—Thalidomide—leprosy	0.000456	0.00327	CcSEcCtD
Irbesartan—JUN—MyD88:Mal cascade initiated on plasma membrane—NOD2—leprosy	0.000454	0.0104	CbGpPWpGaD
Irbesartan—Hypertension—Thalidomide—leprosy	0.000452	0.00324	CcSEcCtD
Irbesartan—Myalgia—Thalidomide—leprosy	0.000445	0.00319	CcSEcCtD
Irbesartan—Arthralgia—Thalidomide—leprosy	0.000445	0.00319	CcSEcCtD
Irbesartan—Chest pain—Thalidomide—leprosy	0.000445	0.00319	CcSEcCtD
Irbesartan—CYP2C8—testis—leprosy	0.000445	0.0112	CbGeAlD
Irbesartan—Anxiety—Thalidomide—leprosy	0.000444	0.00318	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.000442	0.00317	CcSEcCtD
Irbesartan—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL2—leprosy	0.00044	0.0101	CbGpPWpGaD
Irbesartan—Discomfort—Thalidomide—leprosy	0.00044	0.00315	CcSEcCtD
Irbesartan—JUN—MyD88-independent cascade—NOD2—leprosy	0.000436	0.01	CbGpPWpGaD
Irbesartan—PTGS1—tendon—leprosy	0.000436	0.011	CbGeAlD
Irbesartan—Dry mouth—Thalidomide—leprosy	0.000435	0.00312	CcSEcCtD
Irbesartan—JUN—Regulation of nuclear SMAD2/3 signaling—IL10—leprosy	0.000433	0.00994	CbGpPWpGaD
Irbesartan—JUN—Activated TLR4 signalling—RIPK2—leprosy	0.000432	0.00993	CbGpPWpGaD
Irbesartan—JUN—Activated TLR4 signalling—TLR2—leprosy	0.000432	0.00993	CbGpPWpGaD
Irbesartan—Oedema—Thalidomide—leprosy	0.000427	0.00306	CcSEcCtD
Irbesartan—Infection—Thalidomide—leprosy	0.000424	0.00304	CcSEcCtD
Irbesartan—Shock—Thalidomide—leprosy	0.00042	0.00301	CcSEcCtD
Irbesartan—Nervous system disorder—Thalidomide—leprosy	0.000419	0.003	CcSEcCtD
Irbesartan—Thrombocytopenia—Thalidomide—leprosy	0.000418	0.003	CcSEcCtD
Irbesartan—Tachycardia—Thalidomide—leprosy	0.000417	0.00299	CcSEcCtD
Irbesartan—Skin disorder—Thalidomide—leprosy	0.000415	0.00297	CcSEcCtD
Irbesartan—Hyperhidrosis—Thalidomide—leprosy	0.000413	0.00296	CcSEcCtD
Irbesartan—Anorexia—Thalidomide—leprosy	0.000407	0.00292	CcSEcCtD
Irbesartan—JUN—Toll Like Receptor 4 (TLR4) Cascade—RIPK2—leprosy	0.000407	0.00934	CbGpPWpGaD
Irbesartan—JUN—Toll Like Receptor 4 (TLR4) Cascade—TLR2—leprosy	0.000407	0.00934	CbGpPWpGaD
Irbesartan—JUN—Aryl Hydrocarbon Receptor Pathway—IFNG—leprosy	0.0004	0.00919	CbGpPWpGaD
Irbesartan—Hypotension—Thalidomide—leprosy	0.000399	0.00286	CcSEcCtD
Irbesartan—JUN—IL-5 Signaling Pathway—IL2—leprosy	0.000397	0.00913	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—CD8A—leprosy	0.000393	0.00903	CbGpPWpGaD
Irbesartan—JUN—Activated TLR4 signalling—NOD2—leprosy	0.000392	0.009	CbGpPWpGaD
Irbesartan—Musculoskeletal discomfort—Thalidomide—leprosy	0.000389	0.00279	CcSEcCtD
Irbesartan—Paraesthesia—Thalidomide—leprosy	0.000383	0.00275	CcSEcCtD
Irbesartan—JUN—IL-2 Signaling Pathway—IL2—leprosy	0.000382	0.00878	CbGpPWpGaD
Irbesartan—Dyspnoea—Thalidomide—leprosy	0.000381	0.00273	CcSEcCtD
Irbesartan—Somnolence—Thalidomide—leprosy	0.000379	0.00272	CcSEcCtD
Irbesartan—Dyspepsia—Thalidomide—leprosy	0.000376	0.00269	CcSEcCtD
Irbesartan—JUN—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—leprosy	0.000374	0.00859	CbGpPWpGaD
Irbesartan—Decreased appetite—Thalidomide—leprosy	0.000371	0.00266	CcSEcCtD
Irbesartan—JUN—Toll Like Receptor 4 (TLR4) Cascade—NOD2—leprosy	0.000369	0.00847	CbGpPWpGaD
Irbesartan—Gastrointestinal disorder—Thalidomide—leprosy	0.000369	0.00264	CcSEcCtD
Irbesartan—Fatigue—Thalidomide—leprosy	0.000368	0.00264	CcSEcCtD
Irbesartan—PTGS1—Overview of nanoparticle effects—TNF—leprosy	0.000367	0.00842	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—TLR2—leprosy	0.000366	0.00842	CbGpPWpGaD
Irbesartan—Constipation—Thalidomide—leprosy	0.000365	0.00262	CcSEcCtD
Irbesartan—Pain—Thalidomide—leprosy	0.000365	0.00262	CcSEcCtD
Irbesartan—JUN—Toll-Like Receptors Cascades—TLR2—leprosy	0.000362	0.00832	CbGpPWpGaD
Irbesartan—JUN—Toll-Like Receptors Cascades—RIPK2—leprosy	0.000362	0.00832	CbGpPWpGaD
Irbesartan—PTGS1—testis—leprosy	0.000361	0.00908	CbGeAlD
Irbesartan—JUN—Aryl Hydrocarbon Receptor Pathway—IL2—leprosy	0.000355	0.00816	CbGpPWpGaD
Irbesartan—PTGS1—nervous system—leprosy	0.000354	0.00892	CbGeAlD
Irbesartan—JUN—TGF-beta Receptor Signaling—IFNG—leprosy	0.000352	0.00808	CbGpPWpGaD
Irbesartan—JUN—IL2-mediated signaling events—IFNG—leprosy	0.000352	0.00808	CbGpPWpGaD
Irbesartan—Feeling abnormal—Thalidomide—leprosy	0.000352	0.00252	CcSEcCtD
Irbesartan—Gastrointestinal pain—Thalidomide—leprosy	0.000349	0.0025	CcSEcCtD
Irbesartan—AGTR1—Allograft Rejection—IFNG—leprosy	0.000347	0.00798	CbGpPWpGaD
Irbesartan—Urticaria—Thalidomide—leprosy	0.000339	0.00243	CcSEcCtD
Irbesartan—Body temperature increased—Thalidomide—leprosy	0.000337	0.00242	CcSEcCtD
Irbesartan—Abdominal pain—Thalidomide—leprosy	0.000337	0.00242	CcSEcCtD
Irbesartan—JUN—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—leprosy	0.000332	0.00764	CbGpPWpGaD
Irbesartan—JUN—Toll-Like Receptors Cascades—NOD2—leprosy	0.000328	0.00754	CbGpPWpGaD
Irbesartan—JUN—ATF-2 transcription factor network—IFNG—leprosy	0.000328	0.00753	CbGpPWpGaD
Irbesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—leprosy	0.000324	0.00745	CbGpPWpGaD
Irbesartan—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TNF—leprosy	0.000321	0.00737	CbGpPWpGaD
Irbesartan—Hypersensitivity—Thalidomide—leprosy	0.000314	0.00226	CcSEcCtD
Irbesartan—JUN—IL2-mediated signaling events—IL2—leprosy	0.000313	0.00718	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—IL2—leprosy	0.000309	0.00709	CbGpPWpGaD
Irbesartan—Asthenia—Thalidomide—leprosy	0.000306	0.0022	CcSEcCtD
Irbesartan—Pruritus—Thalidomide—leprosy	0.000302	0.00217	CcSEcCtD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—IFNG—leprosy	0.0003	0.00688	CbGpPWpGaD
Irbesartan—CYP2D6—testis—leprosy	0.000297	0.00747	CbGeAlD
Irbesartan—CYP3A4—nervous system—leprosy	0.000296	0.00745	CbGeAlD
Irbesartan—JUN—Regulation of Telomerase—IFNG—leprosy	0.000293	0.00672	CbGpPWpGaD
Irbesartan—Diarrhoea—Thalidomide—leprosy	0.000292	0.00209	CcSEcCtD
Irbesartan—CYP2D6—nervous system—leprosy	0.000291	0.00733	CbGeAlD
Irbesartan—JUN—AP-1 transcription factor network—IFNG—leprosy	0.000286	0.00657	CbGpPWpGaD
Irbesartan—Dizziness—Thalidomide—leprosy	0.000282	0.00202	CcSEcCtD
Irbesartan—JUN—FAS pathway and Stress induction of HSP regulation—TNF—leprosy	0.000278	0.00639	CbGpPWpGaD
Irbesartan—JUN—TWEAK Signaling Pathway—TNF—leprosy	0.000278	0.00639	CbGpPWpGaD
Irbesartan—Vomiting—Thalidomide—leprosy	0.000271	0.00195	CcSEcCtD
Irbesartan—Rash—Thalidomide—leprosy	0.000269	0.00193	CcSEcCtD
Irbesartan—Dermatitis—Thalidomide—leprosy	0.000269	0.00193	CcSEcCtD
Irbesartan—Headache—Thalidomide—leprosy	0.000267	0.00192	CcSEcCtD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—IL2—leprosy	0.000266	0.00612	CbGpPWpGaD
Irbesartan—JUN—Regulation of Telomerase—IL2—leprosy	0.00026	0.00597	CbGpPWpGaD
Irbesartan—JUN—Aryl Hydrocarbon Receptor Pathway—TNF—leprosy	0.000259	0.00595	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—IL10—leprosy	0.000256	0.00588	CbGpPWpGaD
Irbesartan—JUN—AP-1 transcription factor network—IL2—leprosy	0.000254	0.00583	CbGpPWpGaD
Irbesartan—Nausea—Thalidomide—leprosy	0.000254	0.00182	CcSEcCtD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—IFNG—leprosy	0.000252	0.00579	CbGpPWpGaD
Irbesartan—JUN—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—leprosy	0.000242	0.00556	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Receptor Signaling—TNF—leprosy	0.000228	0.00523	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—CD4—leprosy	0.000226	0.00519	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—TNF—leprosy	0.000225	0.00516	CbGpPWpGaD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—IL2—leprosy	0.000224	0.00514	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—IFNG—leprosy	0.000207	0.00475	CbGpPWpGaD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—TNF—leprosy	0.000194	0.00445	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CYLD—leprosy	0.000182	0.00418	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—IFNG—leprosy	0.000166	0.00382	CbGpPWpGaD
Irbesartan—JUN—Apoptosis—TNF—leprosy	0.00016	0.00367	CbGpPWpGaD
Irbesartan—JUN—TNF alpha Signaling Pathway—TNF—leprosy	0.000149	0.00342	CbGpPWpGaD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—TNF—leprosy	0.000137	0.00314	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—leprosy	0.000125	0.00288	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—SDHD—leprosy	0.00012	0.00275	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—RIPK2—leprosy	0.000117	0.00269	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—TLR2—leprosy	0.000117	0.00269	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—leprosy	0.000111	0.00256	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—TNF—leprosy	0.000108	0.00247	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—TNF—leprosy	0.000107	0.00245	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—NOD2—leprosy	0.000106	0.00244	CbGpPWpGaD
Irbesartan—JUN—Immune System—CYLD—leprosy	0.000106	0.00244	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—TNF—leprosy	9.74e-05	0.00224	CbGpPWpGaD
Irbesartan—JUN—Immune System—PARK2—leprosy	9.37e-05	0.00215	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TNF—leprosy	9.18e-05	0.00211	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TNF—leprosy	8.29e-05	0.0019	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—leprosy	8.12e-05	0.00186	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—TNF—leprosy	8.12e-05	0.00186	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—RIPK2—leprosy	7.54e-05	0.00173	CbGpPWpGaD
Irbesartan—JUN—Immune System—TLR2—leprosy	6.83e-05	0.00157	CbGpPWpGaD
Irbesartan—JUN—Immune System—RIPK2—leprosy	6.83e-05	0.00157	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—SDHD—leprosy	6.73e-05	0.00155	CbGpPWpGaD
Irbesartan—JUN—Immune System—NOD2—leprosy	6.2e-05	0.00142	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—RIPK2—leprosy	5.91e-05	0.00136	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—IL2—leprosy	5.63e-05	0.00129	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD40LG—leprosy	5.24e-05	0.0012	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD8A—leprosy	5.18e-05	0.00119	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—IL2—leprosy	5.11e-05	0.00117	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CD4—leprosy	5.11e-05	0.00117	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—RIPK2—leprosy	4.42e-05	0.00101	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—IL2—leprosy	4.41e-05	0.00101	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SDHD—leprosy	4.35e-05	0.000999	CbGpPWpGaD
Irbesartan—JUN—Immune System—HLA-DRB1—leprosy	4.22e-05	0.000969	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—IL2—leprosy	4.01e-05	0.000921	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SDHD—leprosy	3.57e-05	0.00082	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SDHD—leprosy	3.54e-05	0.000813	CbGpPWpGaD
Irbesartan—JUN—Immune System—IFNG—leprosy	3.08e-05	0.000707	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SDHD—leprosy	3.02e-05	0.000695	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL2—leprosy	3.02e-05	0.000693	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD4—leprosy	2.97e-05	0.000683	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL2—leprosy	2.74e-05	0.000629	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL2—leprosy	2.37e-05	0.000544	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SDHD—leprosy	2.33e-05	0.000536	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL2—leprosy	1.77e-05	0.000406	CbGpPWpGaD
